The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.